论文部分内容阅读
目的观察低分子肝素钠联合奥扎格雷钠治疗进展性脑梗死的临床疗效。方法选择符合进展性脑梗死患者120例为研究对象,将其随机分为对照组和治疗组,各60例,对照组给予常规治疗;治疗组在常规治疗基础上采用低分子肝素钠联合奥扎格雷钠治疗。2周为1个疗程。治疗1个疗程后观察两组患者的临床疗效。结果治疗组总有效率为88.3%,明显高于对照组的71.7%,两组疗效比较,差异有统计学意义(P<0.05)。两组患者均未发生严重不良反应。结论低分子肝素钠联合奥扎格雷钠治疗进展性脑梗死,并协同抗凝、抗栓治疗,疗效显著,并发症少,值得在临床上推广。
Objective To observe the clinical effect of low molecular weight heparin combined with ozagrel sodium on patients with progressive cerebral infarction. Methods A total of 120 patients with progressive cerebral infarction were enrolled in this study. They were randomly divided into control group and treatment group, 60 cases in each group. The control group was given routine treatment. The treatment group received low molecular weight heparin combined with Ozal Gray sodium treatment. 2 weeks for a course of treatment. After a course of treatment, the clinical efficacy of the two groups was observed. Results The total effective rate of the treatment group was 88.3%, which was significantly higher than that of the control group (71.7%). There was significant difference between the two groups (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Low molecular weight heparin combined with ozagrel sodium in the treatment of advanced cerebral infarction, and in combination with anticoagulant and antithrombotic therapy have significant curative effect and few complications, so it is worth to be popularized clinically.